Clinical trials: Blood Plasma Therapy
Multiple Myeloma
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
- Trial name
- MonumenTAL-8 (NCT06550895)
- Testing
- Cilta-cel, Talquetamab
- Where
- 9 sites in United States, Australia
- Volunteers
- 11 people
- Sponsor
- Janssen Research & Development, LLC
Idiopathic Pulmonary Fibrosis
Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
This Phase IIb trial will compare effectiveness and safety of a multi-component autoantibody reduction therapy (AART), consisting of therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin (IVIg) for…
- Trial name
- STRIVE II (NCT07674745)
- Testing
- Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin
- Where
- 9 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Alabama at Birmingham
Inflammatory Myofibroblastic Tumor
Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors
Targeted therapy based on target identification by genetic examinations is a promising direction in the treatment of patients with a complicated course of inflammatory myofibroblastic tumor.
- Trial name
- NCT03874273
- Testing
- Crizotinib
- Where
- Russia
- Volunteers
- 25 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This phase I trial tests the safety and side effects of SX-682 in combination with standard of care treatment carfilzomib, daratumumab-hyaluronidase, and dexamethasone in treating patients with multiple myeloma that has come back…
- Trial name
- NCT06622005
- Testing
- Cxcr1/2 Inhibitor SX-682, Daratumumab and Recombinant Human Hyaluronidase, Carfilzomib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Plantar Fascitis
Effects of Autologous Blood Injection Versus Platelet Rich Plasma on Chronic Plantar Fasciitis
To explore effects of Autologous Blood Injection versus Platelet Rich plasma injection for treatment of chronic plantar fasciitis
- Trial name
- PF:AutovsPRP (NCT05240872)
- Testing
- PRP injection, ABI injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul Training and Research Hospital
Multiple Myeloma
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma
This study is a Ph I trial to test the safety of the study drug, hLL1-DOX at different dose levels in patients with recurrent multiple myeloma.
- Trial name
- NCT01101594
- Testing
- hLL1-DOX (the doxorubicin conjugate of milatuzumab)
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Gilead Sciences
Chronic Myeloproliferative Disorders, Infection
Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies
RATIONALE: Antimicrobial solution comprising trimethoprim-sulfamethoxazole, edetate calcium disodium, and ethanol may help prevent blockages and infections from forming in patients with central venous access catheters or…
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma
- Trial name
- NCT01101412
- Testing
- Edetate Calcium Disodium, Ethanol, Trimethoprim-sulfamethoxazole
- Sponsor
- M.D. Anderson Cancer Center
Blood Plasma Therapy, COVID
Convalescent Plasma for COVID-19
The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess: the titer of anti-COVID-19 antibodies in the donors and in the patients before and…
- Trial name
- NCT04365439
- Testing
- Blood plasma
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- Enos Bernasconi
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of etentamig (ABBV-383) when co-administered…
- Trial name
- NCT05259839
- Testing
- Etentamig, Dexamethasone, Lenalidomide
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 283 people
- Sponsor
- AbbVie
Pilonidal Sinus
Minimally Invasive Treatment Methods for Pilonidal Disease
Patients with pilonidal sinus disease will be randomised to two groups (crystallised phenol and platelet rich plasma). Sinus healing time, patient satisfaction, complications and recurrence rates will be compared.
- Trial name
- NCT03070028
- Testing
- crystallised phenol, Platelet rich plasma
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Uşak University
Multiple Myeloma
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of the study is to characterize safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the efficacy of JNJ-68284528 (Phase 2).
- Trial name
- CARTITUDE-1 (NCT03548207)
- Testing
- JNJ-68284528
- Where
- 21 sites in United States, Japan
- Volunteers
- 126 people
- Sponsor
- Janssen Research & Development, LLC
Refractory Plasma Cell Myeloma
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
This phase II trial studies the side-effects and anti-cancer effects of giving an autologous or syngeneic stem cell transplant followed by an allogeneic donor stem cell transplant and bortezomib.
- Trial name
- NCT00793572
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Cyclosporine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma (MM), GI Cancer
Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention
The study investigates taste disorders that commonly occur during or after cancer treatment, often leading to issues such as malnutrition and treatment discontinuation.
- Conditions
- Multiple Myeloma (MM), GI Cancer, Taste Disorder, Melanoma (Skin Cancer)
- Trial name
- GustaborRCT (NCT07649681)
- Testing
- Gustabor server, Standard Recommendations
- Where
- 6 sites in Germany
- Volunteers
- 198 people
- Sponsor
- Wuerzburg University Hospital
Multiple Myeloma
An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1…
- Trial name
- CheckMate 602 (NCT02726581)
- Testing
- Nivolumab, Elotuzumab, Pomalidomide
- Where
- 121 sites in United States, Austria and 14 more
- Volunteers
- 170 people
- Sponsor
- Bristol-Myers Squibb
Cytokine Release Syndrome, Neoplasms
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
Background: Drugs or cell therapies to treat cancer can sometimes cause cytokine release syndrome (CRS). That is, the body makes too many cytokines after treatment. Cytokines are proteins that play a role in the immune system.
- Conditions
- Cytokine Release Syndrome, Neoplasms, Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT07499128
- Testing
- TempTraq, VitalTraq
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Cancer Institute (NCI)
Schizophrenia
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
In this study, investigators designed a double-blind randomized trial to compare the efficacy and safety between sodium valproate, amisulpride and MECT combination therapy in clozapine-treated refractory schizophrenia (CTRS).
- Trial name
- NCT03652974
- Testing
- sodium valproate with Clozapine, modified electroconvulsive therapy(MECT) with Clozapine, amisulpride with Clozapine
- Where
- China
- Volunteers
- 145 people
- Sponsor
- Shanghai Mental Health Center
Acne Vulgaris, Atrophic Acne Scar
Autologous Plasma Gel Injection Versus Polydioxanone Cog Threads Insertion for the Treatment of Atrophic Post-acne Scars: a Split-face
Both male and female patients, with atrophic acne scars All patients underwent one session of subcision before receiving: A: cog PDO threads on one side of the face (one session). B: plasma gel on the other side (one session).
- Trial name
- NCT06580691
- Testing
- Subcision plus Plasma gel injection Vs Subcision plus Cog PDO threads
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Sameh Sarsik
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
This phase II MATCH treatment trial identifiesay block the protein tyrosine kinase WEE1 the effects of AZD1775 in patients whose cancer has a genetic change called BRCA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439227
- Testing
- Adavosertib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- National Cancer Institute (NCI)
Monoclonal Gammopathy of Renal Significance
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
- Trial name
- NCT06418477
- Testing
- Dara-CyBorD
- Where
- 3 sites in China
- Volunteers
- 20 people
- Sponsor
- Peking University People's Hospital
Chronic Myeloproliferative Disorders, Leukemia
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00806767
- Testing
- therapeutic immune globulin, busulfan, fludarabine phosphate
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Institut Paoli-Calmettes
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.